Hahn Brian M.'s Form 4 filing
Crescent Biopharma, Inc.CBIO · filed Jun 20, 2024
- Accession no.
- 0001415889-24-017623
- Filed
- Jun 20, 2024, 4:15 PM ET
- Trade date
- Jun 18, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market purchases total $4.33K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Hahn Brian M.CIK 0001589711 | Officer (SVP Finance, CFO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 18, 2024 | Common Stock | PPurchaseAcquired | +17,500 | $0.2477F1 | +$4,334.75 | 70,643 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The Reporting Person purchased the securities on the open market at purchase prices ranging from $0.2453 to $0.2478 per share, with a weighted average purchase price of $0.2477 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
Referenced by the price of 1 transaction in Table I.